Blue Earth Diagnostics, a subsidiary of Bracco Imaging, is a recognized leader in the development and commercialization of novel PET radio-pharmaceuticals to inform clinical management for cancer patients. Its portfolio includes a commercial product for recurrent prostate cancer and a robust pipeline of investigational agents.
For more information, visit: www.blueearthdiagnostics.com.
Exosome Diagnostics, a Bio-Techne brand, is based outside of Boston, MA with a mission focused on developing and commercializing revolutionary, exosome-based diagnostics to deliver personalized precision healthcare that improves lives.
Our liquid biomarker, ExoDx™ Prostate (IntelliScore), or EPI, is a simple urine test that delivers unique, actionable intelligence to help with the prostate biopsy decision. The EPI score is a standalone test, and not influenced by standard of care or common clinical features such as DRE, family history, or PSA level. Clinical studies demonstrate that the EPI Test improves patient compliance and identifies more high- grade prostate cancers (HGPCa) compared to standard of care alone. EPI is also telemedicine enabled with its At-Home Collection Kit for patients who cannot travel long distances to see their provider.
The ExoDx Prostate Test has been included in the National Comprehensive Cancer Network guidelines (NCCN guidelines) for early detection of prostate cancer since 2019, is covered by Medicare and several private commercial payors, and covered for U.S. Veterans under the General Services Administration (GSA) award.
Visit: ExosomeDx.com
Lantheus is an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find Fight and Follow® serious medical conditions.
For more information, please visit www.lantheus.com.
At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.
Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world’s most threatening diseases, improving the quality of outcomes, and enabling access to care.
We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.
Advanced Accelerator Applications (AAA), a Novartis company, is a medicines company developing targeted RLT and imaging radioligands in oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine.
To learn more please visit www.adacap.com.
.
Focal One® Robotic HIFU is the first and only robotic platform designed for focal ablation of prostate tissue using High Intensity Focused Ultrasound that is controlled by the urologist.
ExactVu™ Micro-Ultrasound Targeted Biopsies is the world’s first and only targeted biopsy system using 29 MHz Micro-Ultrasound technology providing 300% improved resolution over traditional ultrasound.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com.
Profound Medical develops customizable, incision-free therapies which combine real-time Magnetic Resonance (“MR”) imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. We believe TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH).
